PARP Inhibitor Combinations in First Line mCRPC: A Systematic Review and Meta-Analysis.

Rashid K Sayyid,Zachary Klaassen,Alejandro Berlin,Soumyajit Roy,Leonardo R Brandão,Rui Bernardino,Julian Chavarriaga, Di Maria Jiang,Daniel E Spratt,Neil E Fleshner,Christopher J D Wallis

BJU international（2023）

引用 0|浏览12

暂无评分

摘要

PARPi addition to ARATs in the first-line mCRPC setting is associated with rPFS benefits across subgroups, with the greatest magnitude of benefit in BRCA1/2-mutated patients. OS benefits remain inconsistent irrespective of HRRm status, with significant increases in grade≥3 TEAEs, particularly anemia. Currently, we suggest this combination approach be selectively offered to HRRm patients, preferentially BRCA1/2-mutated.

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要